WO2009094279A1 - Quinolizidinone m1 receptor positive allosteric modulators - Google Patents
Quinolizidinone m1 receptor positive allosteric modulators Download PDFInfo
- Publication number
- WO2009094279A1 WO2009094279A1 PCT/US2009/031032 US2009031032W WO2009094279A1 WO 2009094279 A1 WO2009094279 A1 WO 2009094279A1 US 2009031032 W US2009031032 W US 2009031032W WO 2009094279 A1 WO2009094279 A1 WO 2009094279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- pharmaceutically acceptable
- group
- acceptable salt
- Prior art date
Links
- 0 CCCNCC* Chemical compound CCCNCC* 0.000 description 1
- DMSHUVBQFSNBBL-UHFFFAOYSA-N N#Cc(cc1)ncc1Br Chemical compound N#Cc(cc1)ncc1Br DMSHUVBQFSNBBL-UHFFFAOYSA-N 0.000 description 1
- OOOXHSHUTFJANQ-UHFFFAOYSA-N N#Cc(cc1)ncc1N1CCN(CC(C=C2C(N=O)=O)=C(C=CC=C3)N3C2=O)CC1 Chemical compound N#Cc(cc1)ncc1N1CCN(CC(C=C2C(N=O)=O)=C(C=CC=C3)N3C2=O)CC1 OOOXHSHUTFJANQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention is directed to a class of quinolizidinone compounds, their salts, pharmaceutical compositions comprising them and their use in therapy of the human body.
- the invention is directed to a class of quinolizidinone compounds which are muscarinic Ml receptor positive allosteric modulators, and hence are useful in the treatment of Alzheimer's Disease and other diseases mediated by the muscarinic Ml receptor.
- Alzheimer's Disease is a common neurodegenerative disease affecting the elderly, resulting in progressive memory impairment, loss of language and visuospatial skills, and behavior deficits. Characteristics of the disease include degeneration of cholinergic neurons in the cerebral cortex, hippocampus, basal forebrain, and other regions of the brain, neurofibrillary tangles, and accumulation of the amyloid ⁇ peptide (A ⁇ ).
- a ⁇ is a 39-43 amino acid produced in the brain by processing of the beta-amyloid precursor protein (APP) by the beta-amyloid protein cleaving enzyme ("beta secretase" or "BACE”) and gamma- secretase. The processing leads to accumulation of A ⁇ in the brain.
- APP beta-amyloid precursor protein
- BACE beta-amyloid protein cleaving enzyme
- Cholinergic neurotransmission involves the binding of acetylcholine either to the nicotinic acetylcholine receptor (n AChR) or to the muscarinic acetylcholine receptor (m AChR). It has been hypothesized that cholinergic hypofunction contributes to the cognitive deficits of patients suffering from Alzheimer's Disease. Consequently, acetyl cholinesterase inhibitors, which inhibit acetylcholine hydrolysis, have been approved in the United States for use in the treatment of the cognitive impairments of Alzheimer's Disease patients. While acetyl cholinesterase inhibitors have provided some cognitive enhancement in Alzheimer's Disease patients, the therapy has not been shown to change the underlying disease pathology.
- a second potential pharmacotherapeutic target to counteract cholinergic hypofunction is the activation of muscarinic receptors.
- Muscarinic receptors are prevalent throughout the body. Five distinct muscarinic receptors (M1-M5) have been identified in mammals. In the central nervous system, muscarinic receptors are involved in cognitive, behavior, sensory, motor and autonomic functions.
- the muscarinic Ml receptor which is prevalent in the cerebral cortex, hippocampus and striatum, has been found to have a major role in cognitive processing and is believed to have a role in the pathophysiology of Alzheimer's Disease, See Eglen et al, TRENDS in Pharmacological Sciences, 2001, 22:8, 409-414.
- Ml agonists also have the potential to treat the underlying disease mechanism of Alzheimer's Disease.
- the cholinergic hypothesis of Alzheimer's Disease is linked to both ⁇ -amyloid and hyperphosphorylated tau protein. Formation of ⁇ -amyloid may impair the coupling of the muscarinic receptor with G-proteins. Stimulation of the Ml muscarinic receptor has been shown to increase formation of the neuroprotective ⁇ APPs fragment, thereby preventing the formation of the A ⁇ peptide.
- Ml agonists may alter APP processing and enhance ⁇ APPs secretion. See Fisher, Jpn J Pharmacol, 2000, 84:101-112.
- Ml ligands which have been developed and studied for Alzheimer's Disease have produced side effects common to other muscarinic receptor ligands, such as sweating, nausea and diarrhea.
- the muscarinic receptors are known to contain one or more allosteric sites, which may alter the affinity with which muscarinic ligands bind to the primary binding or orthosteric sites. See, e.g., S. Lazareno et al, MoI Pharmacol, 2002, 62:6, 1491-1505; S. Lazareno et al, MoI Pharmacol, 2000, 58, 194-207.
- the compounds of the invention which are muscarinic Ml receptor positive allosteric modulators, are believed to be useful in the treatment of Alzheimer's Disease and other diseases mediated by the muscarinic Ml receptor.
- the present invention is directed to novel quinolizidinone compounds of generic formula (I)
- the invention is further directed to methods of treating a patient (preferably a human) for diseases or disorders in which the Ml receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof.
- a patient preferably a human
- diseases or disorders in which the Ml receptor is involved such as Alzheimer's disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders
- the invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.
- the invention is directed to compounds of general formula (I)
- X 1 is selected from the group consisting of (I) N,
- X 2 is CHR 7 or CH 2 CHR 7 ;
- Rl and R2 are each selected from the group consisting of
- R 7 is hydrogen or R 1 and R 7 are linked together to form -CH 2 - or -CH 2 CH 2 -;
- R3 is selected from the group consisting of
- R 3 alkyl, aryl, heteroaryl, heterocyclic or cycloalkyl moiety is optionally substituted with one or more
- R4 is selected from the group consisting of (1) hydrogen, (2) -Ci -6 alkyl, and wherein said R4 alkyl or aryl moiety is optionally substituted with one or more
- R5 is selected from the group consisting of (1) hydrogen, (2) -Ci_6 alkyl, (3) TM(CH2)n-aryl, or
- R6A and RoB are independently selected from the group consisting of
- n, q are each selected from 0, 1 or 2;
- Rl is hydrogen or -Ci_3 alkyl, preferably methyl
- R2 is hydrogen or methyl. In particular embodiments of the compounds of formula (I), at least one of Rl and R2 is hydrogen.
- Rl and R2 together form oxo.
- R3 is selected from the group consisting of
- heteroaryl group having 5 to 12 ring atoms (preferably from 5 to 10 ring atoms),
- R3 heteroaryl groups include pyridyl, pyriniidinyl, pyrazolyl, benzimidazolyl, benzothiophene, quinolinyl, indolyl, quinazolinyl, quinoxalinyl, pyrazinyl, benzofuran, benzothiazole and benzodioxanyl, all of which may be substituted as described above.
- Preferred R3 aryl groups include phenyl, indanyl and napthyl, all of which may be substituted as described above.
- Preferred IIS alkyl groups include methyl.
- Preferred R? cycloalkyl groups include adamantyl.
- Exemplary R.3 groups include the following:
- R4 is hydrogen.
- R.5 is hydrogen.
- R5 is selected from the group consisting of optionally substituted
- -C ⁇ -6 alkyl for example, methyl, ethyl, isopropyl
- heteroaryl group having 5 to 12 ring atoms for example, furanyl, thienyl, pyridyl and benzodioxolyl.
- Exemplary R$ aryl groups include phenyl and napthyl.
- the invention is directed to methods of treating a patient (preferably a human) for diseases in which the Ml receptor is involved, such as Alzheimer's Disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of general formula (I).
- a patient preferably a human
- diseases in which the Ml receptor is involved such as Alzheimer's Disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders
- the invention is also directed to the use of a compound of formula (I) for treating diseases or disorders in which the Ml receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders.
- the invention is also directed to medicaments or pharmaceutical compositions for treating diseases or disorders in which the Ml receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders, which comprise a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- diseases or disorders in which the Ml receptor is involved such as Alzheimer's disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders, which comprise a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the invention is further directed to a method for the manufacture of a medicament or a composition for treating diseases or disorders in which the Ml receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders, comprising combining a compound of formula (I) with one or more pharmaceutically acceptable carriers.
- R 3 is pyridyl, which is optionally substituted with one or more
- R 1 , R 2 , R 3 and R 4 are as defined above, and R 6 is present at one or more of the ring atoms, and is selected from the group consisting of (l) hydroxyl,
- R 1 and R 1 ⁇ are linked together to form - CH 2 - or -CH 2 CH 2 -, R is hydrogen, and R is as defined above.
- Exemplary groups formed by linking R 1 and R 1A are 2,5-diazabicyclo [2.2.2] octane and 3,8-diazabicyclo [3.2.1.] octane.
- R 1 , R 2 and R 5 are as defined above, and X' is selected from O, S or SO 2 .
- R 1 , R 2 , R 3 and R 4 are as described above.
- Specific embodiments of formula (I) are described herein as Examples 1-179, such as 4-oxo- 1 -( ⁇ 4-[4-(trifluoromethyl)phenyl]pi ⁇ erazin- 1 -yl ⁇ methyl)-4H-quinolizine-3-carboxylic acid;
- the invention is also directed to methods of treating a patient (preferably a human) for diseases or disorders in which the Ml receptor is involved, such as Alzheimer's Disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of formulae (II) to (VI) 5 or a pharmaceutically acceptable salt thereof.
- the invention is also directed to the use of a compound of formulae (II) to (VI) for treating a disease or disorder in which the Ml receptor is involved, such as Alzheimer's Disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders, by administering to the patient a compound of formulae (II) to (VI), or a pharmaceutically acceptable salt thereof,
- a disease or disorder in which the Ml receptor is involved such as Alzheimer's Disease, cognitive impairment, schizophrenia, pain disorders and sleep disorders
- the invention is also directed to medicaments or pharmaceutical compositions for the treatment of diseases or disorders in a patient (preferably a human) in which the Ml receptor is involved, such as Alzheimer's Disease, cognitive impairment, schizophrenia, pain disorders, and sleep disorders, which comprise a compound of formulae (II) to (VI), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the invention is also directed to a method for the manufacture of a medicament or a pharmaceutical composition for treating diseases in which Ml receptor is involved, such as Alzheimer's Disease, cognitive impairment, schizophrenia, pain disorders, and sleep disorders, comprising combining a compound of formulae (II) to (VI), or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.
- diseases in which Ml receptor is involved such as Alzheimer's Disease, cognitive impairment, schizophrenia, pain disorders, and sleep disorders
- a pharmaceutically acceptable salt thereof a pharmaceutically acceptable carrier.
- alkyl by itself or as part of another substituent, means a saturated straight or branched chain hydrocarbon radical having the number of carbon atoms designated (e.g., C 1.10 alkyl means an alkyl group having from one to ten carbon atoms).
- Preferred alkyl groups for use in the invention are Cl -6 alkyl groups, having from one to six atoms.
- Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.
- Co alkyl means a bond.
- the terra "alkenyl,” by itself or as part of another substituent means a straight or branched chain hydrocarbon radical having a single carbon-carbon double bond and the number of carbon atoms designated (e.g., C2-10 alkenyl means an alkenyl group having from two to ten carbon atoms).
- Preferred alkenyl groups for use in the invention are C2-6 alkenyl groups, having from two to six carbon atoms.
- Exemplary alkenyl groups include ethenyl and propenyl.
- alkynyl by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon triple bond and the number of carbon atoms designated (e.g., C2-10 alkynyl means an alkynyl group having from two to ten carbon atoms).
- Preferred alkynyl groups for use in the invention are C2-6 alkynyl groups, having from two to six carbon atoms.
- Exemplary alkynyl groups include ethynyl and propynyl.
- cycloalkyl by itself or as part of another substituent, means a means a saturated cyclic hydrocarbon radical having the number of carbon atoms designated (e.g., C3-12 cycloalkyl means a cycloalkyl group having from three to twelve carbon atoms).
- cycloalkyl as used herein includes mono-, bi- and tricyclic saturated carbocycles, as well as bridged and fused ring carbocycles, such as spiro fused ring systems.
- Preferred cycloalkyl groups for use in the invention are monocyclic C3.8 cycloalkyl groups, having from three to eight carbon atoms.
- Exemplary monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- Exemplary bridged cycloalkyl groups include adamantly and norbornyl.
- Exemplary fused cycloalkyl groups include decahydronaphthalene.
- aryl by itself or as part of another substituent, means an aromatic cyclic hydrocarbon radical.
- Preferred aryl groups have from six to ten carbons atoms.
- aryl includes multiple ring systems as well as single ring systems.
- Preferred aryl groups for use in the invention include phenyl and naphthyl.
- aryl also includes fused cyclic hydrocarbon rings which are partially aromatic (i.e., one of the fused rings is aromatic and the other is non-aromatic).
- An exemplary aryl group which is partially aromatic is indanyl.
- halo or halogen includes fluoro, chloro, bromo and iodo.
- heteroaryl by itself or as part of another substituent, means a cyclic or polycyclic group having ring carbon atoms and at least one ring heteroatom (O, N or S), wherein at least one of the constituent rings is aromatic.
- heteroaryl groups for use in the invention include carbazolyl, carbolinlyl, chromenyl, cinnolinyl, furanyl, benzofuranyl, benzofurazanyl, isobenzofuranyl, imidazolyl, benzimidazolyl, benzimidazolonyl, indazolyl, indolyl, isoindolyl, indolinyl, indolazinyl, indynyl, oxadiazolyl,oxazolyl, benzoxazolyl, ⁇ soxazolyl, pyranyl, pyrazinyl, pyrazolyl, benzopyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolyl, isoquinolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, thienyl,
- R3 and R5 heteroaryl groups have from 5 to 12 ring atoms.
- the heteroaryl groups have 5 or 6 ring atoms.
- one subgroup of R.3 and R.5 heteroaryl groups have 5 or 6 ring atoms and a single heteroatom, which is nitrogen.
- Exemplary heteroaryl groups in this embodiment are pyridyl and pyrrolyl.
- R3 and R5 heteroaryl groups have 5 or 6 ring atoms and two heteroatoms, which are selected from sulfur and nitrogen.
- exemplary heteroaryl groups in this embodiment are pyrazolyl, im ⁇ dazolyl, thienyl and isothiazolyl.
- R ⁇ and R5 heteroaryl groups has 7 or 8 ring atoms and two heteroatoms, which are selected from oxygen, sulfur and nitrogen.
- exemplary heteroaryl groups in this embodiment are benzoxazolyl, benzothiazolyl and quinoxalinyl.
- heteroaryl also includes fused cyclic heterocyclic rings which are partially aromatic (i.e., one of the fused rings is aromatic and the other is non-aromatic).
- An exemplary heteroaryl group which is partially aromatic is benzodioxol.
- the substituent may be bonded to a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution.
- the substituent is bonded to a ring carbon atom.
- the point of attachment may be at a ring carbon atom of the heteroaryl group, or on a ring heteroatom
- heterocyclic by itself or as part of another substituent, means a cycloalkyl group as defined above, in which one or more of the ring carbon atoms is replaced with a heteroatom (such as N or O).
- Suitable non-aromatic heterocyclic groups for use in the invention include piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, pyrazolidinyl and imidazolildinyl.
- heterocyclic groups for use in the invention have four to eight ring atoms and a single nitrogen or oxygen heteroatom.
- the substituent When a heterocyclic group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heterocyclic group, or to a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution.
- a heterocyclic group when a heterocyclic group is defined as a substituent herein, the point of attachment may be at a ring carbon atom of the heterocyclic group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits attachment.
- the compounds of the invention may have one or more asymmetric centers.
- Compounds with asymmetric centers give rise to enantiomers (optical isomers), diastereomers (configurational isomers) or both, and it is intended that all of the possible enantiomers and diastereomers in mixtures and as pure or partially purified compounds are included within the scope of this invention.
- the present invention is meant to encompass all such isomeric forms of the compounds of formulae (I) to (VI).
- Formulae (I) to (VI) are shown above without a definite stereochemistry at certain positions.
- the present invention includes all stereoisomers of formulae (I) to (VI) and pharmaceutically acceptable salts thereof.
- racemic mixtures of the compounds may be separated so that the individual enantiomers or diastereomers are isolated.
- the separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
- the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
- the diastereomeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
- the racemic mixture of the compounds can also be separated directly by chromatographic methods using chiral stationary phases, which methods are well known in the art.
- any enantiomer or diastereomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
- the compounds of the invention may be prepared according to the following reaction
- Compound 1 is described in the literature (J. Am. Chem. Soc; 126; 50; 2004; 16353 - 16360) and can be hydrolyzed to the carboxylic acid using a base like sodium hydroxide, which can undergo reductive amination with an amine such as 2 a using a reducing agent like sodium cyanoborohydride in an appropriate solvent to afford Example 1.
- a base like sodium hydroxide
- the reduction may be carried out directly on ethyl ester 1, followed by reductive amination with piperazine 2b.
- Subsequent hydrolysis of the ester group can be carried out using a base like sodium hydroxide in solvents such as THF, ethanol, or DMSO to afford Example 125.
- Piperazine derivative 4 containing a protecting group such as tert- butyloxycarbonyl (B oc), can be arylated under using a base like potassium carbonate in a solvent such as DMSO with an aryl halide such as 5.
- Metal catalysts such as copper or palladium may also be added to facilitate the reaction. Removal of the Boc protecting can be done out using an acid such as HCl in a solvent like ethyl acetate to afford piperazine 6, which can undergo reductive amination as shown in Scheme 1 to provide Example 2.
- compound 1 may be reduced with a reagent like sodium borohydride and converted to the chloride using a reagent like methane sulfonyl chloride (MsCl) in a solvent like dichloromethane.
- MsCl methane sulfonyl chloride
- Nucleophilic displacement of chloride 7 can be carried out using an amine like morpholine 8 with an appropriate base such as potassium carbonate.
- Final hydrolysis as shown in Scheme 1 can provide Example 3.
- compound 9 can undergo a cross coupling reaction with an alkyl, aryl, or vinyl metal species such as zinc or boron using a transition metal like palladium and a phosphine ligand with a base like cesium carbonate in solvents like THF. Hydrolysis of the ester affords Example 148.
- the vinyl group of Example 148 may be further reduced using a catalyst like palladium on carbon in a solvent like MeOH under a hydrogen atmosphere to provide ethyl Example 152.
- the chlorine in compound 9 may be displaced with a variety of nucleophiles such sodium methanethiolate in a solvent like DMSO followed by hydrolysis to afford Example 153.
- the sulfide can also undergo oxidation to provide sulfone Example 154 using an oxidant like osmium tetraoxide.
- Ketopiperazine 11 may be alkylated using a base like sodium hydride in a solvent like DMSO with electrophiles such as methyl iodide to provide example 155.
- Arylation of 9 may also be carried out using a catalyst such as copper iodide with a base like cesium carbonate and an aryl halide like iodobenzene to afford Example 160.
- the present invention also provides a method for the synthesis of compounds useful as intermediates in the preparation of compounds of the invention.
- any of the above synthetic sequences it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W.McOmie, Plenum Press, 1973, and T.W. Greene & P/G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons > 1991.
- the protecting groups may be removed at a convenient sequent stage using methods known from the art.
- substantially pure means that the isolated material is at least 90% pure, and preferably 95% pure, and even more preferably 99% pure as assayed by analytical techniques known in the art.
- muscarinic Ml receptor refers to one of the five subtypes of the muscarinic acetylcholine receptor, which is from the superfamily of G-protein coupled receptors.
- the family of muscarinic receptors is described, for example, in Pharmacol Ther, 1993, 58:319-379; Eur J Pharmacol, 1996, 295:93-102, and MoI Pharmacol, 2002, 61 :1297- 1302.
- the muscarinic receptors are known to contain one or more allosteric sites, which may alter the affinity with which muscarinic ligands bind to the primary binding or 5 orthosteric sites. See, e.g., S. Lazareno et al, MoI Pharmacol, 2002, 62:6, 1491-1505.
- the terms "positive allosteric modulator” and “allosteric potentiator” are used interchangeably, and refer to a ligand which interacts with an allosteric site of a receptor to activate the primary binding site.
- the compounds of the invention are positive allosteric modulators of the muscarinic Ml receptor.
- a modulator or potentiator o may directly or indirectly augment the response produced by the endogenous ligand (such as acetylcholine or xanomeline) at the orthosteric site of the muscarinic Ml receptor in an animal, in particular, a human.
- the actions of ligands at allosteric receptor sites may also be understood according to the "allosteric ternary complex model," as known by those skilled in the art.
- the allosteric s ternary complex model is described with respect to the family of muscarinic receptors in Birdsall et al, Life Sciences, 2001, 68:2517-2524.
- Christopoulos Nature Reviews: Drug Discovery, 2002, 1:198- 210.
- the compounds of the invention bind to an allosteric binding site0 that is distinct from the orthosteric acetylcholine site of the muscarinic Ml receptor, thereby augmenting the response produced by the endogenous ligand acetylcholine at the orthosteric site of the Ml receptor. It is also believed that the compounds of the invention bind to an allosteric site which is distinct from the xanomeline site of the muscarinic Ml receptor, thereby augmenting the response produced by the endogenous ligand xanomeline at the 5 orthosteric site of the Ml receptor.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids.
- the compounds of the invention may be mono, di or tris salts, depending on the number of acid functionalities present in the free base form of the compound.0
- Free bases and salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.
- Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates.
- Salts derived from pharmaceutically acceptable organic non-toxic bases5 include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, iV,iV'-dibenzylethylene-dianime, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, iV-ethyl-morpholine, iV-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, tri
- salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
- acids include acetic, trifluoroacetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methane sulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, o tartaric, p-toluenesulfonic acid, and the like.
- the present invention is directed to the use of the compounds of formulae (I) to (VI) disclosed herein as Ml allosteric modulators in a patient or subject such as a mammal in need of such activity, comprising the administration of an effective amount of the compound.
- a variety of other mammals can be treated according to the method of the present 5 invention.
- the compounds of the present invention have utility in treating or ameliorating Alzheimer's disease.
- the compounds may also be useful in treating or ameliorating other diseases mediated by the muscarinic Ml receptor, such as schizophrenia, sleep disorders, pain disorders (including acute pain, inflammatory pain and neuropathic pain) and cognitive disorders0 (including mild cognitive impairment).
- Parkinson's Disease pulmonary hypertension
- chronic obstructive pulmonary disease COPD
- asthma urinary incontinence
- glaucoma schizophrenia, Trisomy 21 (Down Syndrome), cerebral amyloid angiopathy, degenerative dementia, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D), Creutzfeld- Jakob disease, prion5 disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, pancreatitis, inclusion body myositis, other peripheral amyloidoses, diabetes, autism and atherosclerosis.
- COPD chronic obstructive pulmonary disease
- COPD chronic obstructive pulmonary disease
- asthma urinary incontinence
- glaucoma schizophrenia
- Trisomy 21 (Down Syndrome) cerebral amyloid angiopathy
- degenerative dementia Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type
- the compounds of the invention are useful in treating Alzheimer's Disease, cognitive disorders, schizophrenia, pain disorders and sleep disorders.
- the compounds may be useful for the prevention of dementia of the Alzheimer's type, as well as for the treatment of early stage, intermediate stage or late stage dementia of the Alzheimer's type.
- schizophrenia conditions or disorders for which the compounds of the invention may be useful include one or more of the following conditions or diseases: 5 schizophrenia or psychosis including schizophrenia (paranoid, disorganized, catatonic or undifferentiated), schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition and substance-induced or drug-induced (phencyclidine, ketanimine and other dissociative anaesthetics, amphetamine and other psychostimulants and cocaine) psychosispsychotic disorder, psychosis associated with affective disorders, brief reactive psychosis, schizoaffective psychosis, "schizophrenia-spectrum” disorders such as schizoid or schizotypal personality disorders, or illness associated with psychosis (such as major depression, manic depressive (bipolar) disorder, Alzheimer's disease and post-traumatic stress syndrome), including both the positive and the negative symptoms of schizophrenia and other psychoses; cognitive disorders including dementia (associated with Alzheimer's disease
- the present invention provides a method for treating schizophrenia or psychosis comprising: administering to a patient in need thereof an effective amount of a compound of the present invention.
- schizophrenia or psychosis pathologies are paranoid, disorganized, catatonic or undifferentiated schizophrenia and substance-induced psychotic disorder.
- DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders
- the text revision of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (2000, American Psychiatric Association, Washington DC) provides a diagnostic tool that includes paranoid, disorganized, catatonic or undifferentiated schizophrenia and substance-induced psychotic disorder.
- the term "schizophrenia or psychosis” includes treatment of those mental disorders as described in DSM-IV-TR.
- schizophrenia or psychosis is intended to include like disorders that are described in other diagnostic sources.
- combinations of the compounds include combinations with agents for the treatment of schizophrenia, for example in combination with sedatives, hypnotics, anxiolytics, antipsychotics, antianxiety agents, cyclopyrrolones, imidazopyridines, pyrazolopyrimidines, minor tranquilizers, melatonin agonists and antagonists, melatonergic agents, benzodiazepines, barbiturates, 5HT-2 antagonists, and the like, such as: adinazolam, allobarbital, alonimid, alprazolam, amisulpride, amitriptyline, amobarbital, amoxapine, aripiprazole, bentazepam, benzoctamine, brotizolam, bupropion, busprione, butabarbital, butalbital, capuride, carbocloral, chloral betaine, chloral hydrate, clomipramine, clonazepam, cloperidone,
- the subject compound may be employed in combination with levodopa (with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide), anticholinergics such as biperiden (optionally as its hydrochloride or lactate salt) and trihexyphenidyl (benzhexol) hydrochloride, COMT inhibitors such as entacapone, MOA-B inhibitors, antioxidants, A2a adenosine receptor antagonists, cholinergic agonists, NMDA receptor antagonists, serotonin receptor antagonists and dopamine receptor agonists such as alentemol, bromocriptine, fenoldopam, lisuride, naxagolide, pergolide and pramipexole.
- levodopa with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide
- anticholinergics such as biperi
- the dopamine agonist may be in the form of a pharmaceutically acceptable salt, for example, alentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate.
- a pharmaceutically acceptable salt for example, alentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate.
- the subject compound may be employed in combination with a compound from the phenothiazine, thioxanthene, heterocyclic dibenzazepine, butyrophenone, diphenylbutylpiperidine and indolone classes of neuroleptic agent.
- phenothiazines include chlorpromazine, mesoridazine, thioridazine, acetophenazine, fiuphenazine, perphenazine and trifluoperazine.
- Suitable examples of thioxanthenes include chlorprothixene and thiothixene.
- An example of a dibenzazepine is clozapine.
- An example of a butyrophenone is haloperidol.
- An example of a diphenylbutylpiperidine is pimozide.
- An example of an indolone is molindolone.
- Other neuroleptic agents include loxapine, sulpiride and risperidone.
- the neuroleptic agents when used in combination with thesubject compound may be in the form of a pharmaceutically acceptable salt, for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fiuphenazine hydrochloride, flurphenazine enathate, fiuphenazine decanoate, trifluoperazine hydrochloride, thiothixene hydrochloride, haloperidol decanoate, loxapine succinate and molindone hydrochloride, Perphenazine, chlorprothixene, clozapine, haloperidol, pimozide and risperidone are commonly used in a non-salt form.
- a pharmaceutically acceptable salt for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazin
- the subject compound may be employed in combination with acetophenazine, alentemol, aripiprazole, amisuipride, benzhexol, bromocriptine, biperiden, chiorpromazine, chlorprothixene, clozapine, diazepam, fenoldopam, fluphenazine, haloperidol, levodopa, levodopa with benserazide, levodopa with carbidopa, lisuride, loxapine, mesoridazine, molindolone, naxagolide, olanzapine, pergolide, perphenazine, pimozide, pramipexole, quetiapine, risperidone, sulpiride, tetrabenazine, frihexyphenidyl, thioridazine, thiothixene, tri
- Potential sleep conditions or disorders for which the compounds of the invention may be useful include enhancing sleep quality; improving sleep quality; augmenting sleep maintenance; increasing the value which is calculated from the time that a subject sleeps divided by the time that a subject is attempting to sleep; decreasing sleep latency or onset (the time it takes to fall asleep); decreasing difficulties in falling asleep; increasing sleep continuity; decreasing the number of awakenings during sleep; decreasing nocturnal arousals; decreasing the time spent awake following the initial onset of sleep; increasing the total amount of sleep; reducing the fragmentation of sleep; altering the timing, frequency or duration of REM sleep bouts; altering the timing, frequency or duration of slow wave (i.e.
- Pain disorders for which the compounds of the invention may be useful include neuropathic pain (such as postherpetic neuralgia, nerve injury, the "dynias", e.g., vulvodynia, phantom limb pain, root avulsions, painful diabetic neuropathy, painful traumatic mononeuropathy, painful polyneuropathy); central pain syndromes (potentially caused by virtually any lesion at any level of the nervous system); postsurgical pain syndromes (eg, postmastectomy syndrome, postthoracotomy syndrome, stump pain); bone and joint pain (osteoarthritis), repetitive motion pain, dental pain, cancer pain, myofascial pain (muscular injury, fibromyalgia); perioperative pain (general surgery, gynecological), chronic pain, dysmermorhea, as well as pain associated with angina, and inflammatory pain of varied origins (e.g.
- neuropathic pain such as postherpetic neuralgia, nerve injury, the "dyni
- osteoarthritis rheumatoid arthritis, rheumatic disease, teno- synovitis and gout
- headache migraine and cluster headache, headache, primary hyperalgesia, secondary hyperalgesia, primary allodynia, secondary allodynia, or other pain caused by central sensitization.
- Compounds of the invention may also be used to treat or prevent dyskinesias.
- compounds of the invention may be used to decrease tolerance and/or dependence to opioid treatment of pain, and for treatment of withdrawal syndrome of e.g., alcohol, opioids, and cocaine.
- the subject or patient to whom the compounds of the present invention is administered is generally a human being, male or female, in whom Ml allosteric modulation is is desired, but may also encompass other mammals, such as dogs, cats, mice, rats, cattle, horses, sheep, rabbits, monkeys, chimpanzees or other apes or primates, for which treatment of the above noted disorders is desired.
- the compounds of the present invention may be used in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the present invention have utility, where the combination of the drugs together are safer or more effective than either drug alone.
- the compounds of the present invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the present invention.
- Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with the compounds of the present invention.
- the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to the compounds of the present invention.
- the combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.
- combinations of the compounds of the present invention include combinations with anti- Alzheimer's Disease agents, for example beta-secretase inhibitors; alpha 7 nicotinic agonists, such as ABT089, SSR180711 and MEM63908; ADAM 10 ligands or activators; gamma-secretase inhibitors, such as LY450139 and TAK 070; gamma secretase modulators; tau phosphorylation inhibitors; glycine transport inhibitors; LXR ⁇ agonists; A ⁇ oE4 conformational modulators; NR2B antagonists; androgen receptor modulators; blockers of A ⁇ oligomer formation; 5-HT4 agonists, such as PRX-03140; 5-HT6 antagonists, such as GSK 742467, SGS-518, FK-962, SL-65.0155, SRA-333 and xaliproden; 5-HTla antagonists, such as lecozotan; p25/CDK5 inhibitors; NK1/
- GSK3 ⁇ inhibitors including AZD 1080, SAR502250 and CEP 16805; neuronal nicotinic agonists; selective Ml agonists; HDAC inhibitors; and microtubule affinity regulating kinase (MARK) ligands; or other drugs that affect receptors or enzymes that either increase the efficacy, safety, convenience, or reduce unwanted side effects or toxicity of the compounds of the present invention.
- AZD 1080, SAR502250 and CEP 16805 neuronal nicotinic agonists
- selective Ml agonists selective Ml agonists
- HDAC inhibitors HDAC inhibitors
- microtubule affinity regulating kinase (MARK) ligands or other drugs that affect receptors or enzymes that either increase the efficacy, safety, convenience, or reduce unwanted side effects or toxicity of the compounds of the present invention.
- MARK microtubule affinity regulating kinase
- combinations of the compounds include combinations with agents for the treatment of pain, for example non-steroidal anti-inflammatory agents, such as aspirin, diclofenac, duflunisal, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, naproxen, oxaprozin, piroxicam, sulindac and tolmetin; COX-2 inhibitors, such as celecoxib, rofecoxib, valdecoxib, 406381 and 644784; CB-2 agonists, such as 842166 and SAB378; VR-I antagonists, such as AMG517, 705498, 782443, PAC20030, Vl 14380 and A425619; bradykinin B 1 receptor antagonists, such as SSR240612 and NVPSAAl 64; sodium channel blockers and antagonists, such as VX409 and SPI860; nitric oxide syntha
- the compounds of the present invention may be administered in combination with compounds useful for enhancing sleep quality and preventing and treating sleep disorders and sleep disturbances, including e.g., sedatives, hypnotics, anxiolytics, antipsychotics, antianxiety agents, antihistamines, benzodiazepines, barbiturates, cyclopyrrolones, orexin antagonists, alpha- 1 antagonists, GABA agonists, 5HT-2 antagonists including 5HT-2A antagonists and 5HT- 2A/2C antagonists, histamine antagonists including histamine H3 antagonists, histamine H3 inverse agonists, imidazopyridines, minor tranquilizers, melatonin agonists and antagonists, melatonergic agents, other orexin antagonists, orexin agonists, prokineticin agonists and antagonists, pyrazolopyrimJdines, T-type calcium channel antagonists, triazolopyridines, and the like, such as: adinazolam
- the subject compound may be employed in combination with levodopa (with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide), anticholinergics such as biperiden (optionally as its hydrochloride or lactate salt) and trihexyphenidyl (benzhexol) hydrochloride, COMT inhibitors such as entacapone, MOA-B inhibitors, antioxidants, A2a adenosine receptor antagonists, cholinergic agonists and dopamine receptor agonists such as alentemol, bromocriptine, fenoldopam, lisuride, naxagolide, pergolide and pramipexole.
- levodopa with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide
- anticholinergics such as biperiden (optionally as its hydrochloride or lactate salt)
- composition as used herein is intended to encompass a product comprising specified ingredients in predetermined amounts or proportions, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- This term in relation to pharmaceutical compositions is intended to encompass a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
- compositions are prepared by uniformly and intimately 5 bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
- the active compound which is a compound of formulae (I) to (VI)
- the pharmaceutical compositions of the present invention encompass any o composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
- the pharmaceutical compositions of the present invention can be presented as discrete units suitable5 for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
- the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil- in-water emulsion or as a water-in-oil liquid emulsion.
- the compounds of the invention, or pharmaceutically acceptable salts thereof may0 also be administered by controlled release means and/or delivery devices.
- compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide 5 pharmaceutically elegant and palatable preparations.
- Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example0 starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a tablet containing the composition of this invention may be prepared by compression or5 molding, optionally with one or more accessory ingredients or adjuvants.
- Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- Each tablet preferably contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule preferably containing from about 0.1 mg to about 500 mg of the active ingredient.
- compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
- compositions include aqueous suspensions, which contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may also contain various excipients.
- the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions, which may also contain excipients such as sweetening and flavoring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension, or in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
- the final injectable form must be sterile and must be effectively fluid for easy syringability.
- the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency. Pharmaceutical compositions of this invention can also be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art.
- administering a should be understood to mean providing a compound of the invention to the individual in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically useful amount, including, but not limited to: oral dosage forms, such as tablets, capsules, syrups, suspensions, and the like; injectable dosage forms, such as IV, IM, or IP 5 and the like; transdermal dosage forms, including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and the like; and rectal suppositories,
- effective amount or “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical
- treatment means any administration of a compound of the present invention and includes (1) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or (2) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology).
- the compositions containing compounds of the present invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
- unit dosage form is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person administering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages.
- Typical examples of unit dosage forms are tablets or capsules for oral administration, single dose vials for injection, or suppositories for rectal administration. This list of unit dosage forms is not intended to be limiting in any way, but merely to represent typical examples of unit dosage forms.
- compositions containing compounds of the present invention may conveniently be presented as a kit, whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person administering the drug to the patient.
- kits may be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient.
- the compounds of the present invention are administered at a daily dosage of from about 0.1 mg to about 100 mg per kg of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
- the total daily dosage is from about 1.0 mg to about 2000 mg, preferably from about 0.1 mg to about 20 rag per kg of body weight. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 1,400 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response.
- the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- a formulation intended for the oral administration to humans may conveniently contain from about 0.005 mg to about 2.5 g of active agent, compounded with an appropriate and convenient amount of carrier material.
- Unit dosage forms will generally o contain between from about 0.005 mg to about 1000 mg of the active ingredient, typically 0.005, 0.01 mg, 0.05 mg, 0.25 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg, administered once, twice or three times a day.
- the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the5 activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
- EmrysTM process vial a mixture of the 1 ⁇ formyl-4-oxo-4H-0 quinoHzine-3-carboxylic acid (77 mg, 0,36 mmol), l-[4 ⁇ (trifluoromethyl)phenyl]piperazine (1 14 mg, 0.50 mmol), glacial acetic acid (0.12 mL, 2.1 mmol) and 1.8 niL of dichloroethane was stirred vigorously. To the stirring mixture was added resin-bound MP-cyanoborohydride (44.6 mg, 0.71 raraol). The mixture was heated via Emrys OptimizerTM microwave to 120 0 C for 30 minutes.
- Example L The following compounds in Table 1 were prepared according to the general procedure provided in Example L
- the starting materials are either commercially available, known in the literature or may be prepared from commercially available reagents using conventional reactions well known in the art.
- Triethylamine (0.075 mL, 0.541 mmol) was added, followed by lrifluoroacetic anhydride (0.038 mL, 0.271 mmol). The reaction was stirred for 1 hour, then was diluted with additional 20 mL of JO DCM and washed with water (2 x 40 mL). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to afford tert-butyl 4-(2-cyano-l -benzofuran- 5- yl)piperazine- 1 -carboxylale.
- Example 148 The following compounds in Table 2 were prepared according to the general procedure provided in Example 148.
- the starting materials are either commercially available, known in the literature or may be prepared from commercially available reagents using conventional reactions well known in lhe art.
- Example 155 The following compounds in Table 3 were prepared according to the general procedure provided in Example 155.
- the starting materials are either commercially available, known in the literature or may be prepared from commercially available reagents using conventional reactions well known in the art.
- EmrysTM process vial a mixture of the l-formyl-4-oxo-4H- quinolizine-3 -carboxylic acid (53 mg, 0.24 mmol), 1 ,4-diazepane (29 mg, 0.29 mmol), glacial acetic acid (0.084 mL, 1.5 mmol) and 1.2 mL of d ⁇ chloroethane was stirred vigorously. To the stirring mixture was added resin-bound MP-cyanoborohydride (239 mg, 0.49 mmol). The mixture was heated via Emrys OptimizerTM microwave to 120 0 C for 20 minutes.
- Example 161 The following compounds in Table 4 were prepared according to the general procedure provided in Example 161.
- the starting materials are either commercially available, known in the literature or may be prepared from commercially available reagents using conventional reactions well known in the art.
- the ethyl l ⁇ formyl-4-oxo-4H-quinolizine-3-carboxylate (5 g, 20.4 mmol) was stirred in a 2: 1 dichloromethane:MeOH solution (102 mL) and cooled to 0 0 C.
- the reaction was treated with sodium borohydride (0.309 g, 8.16 mmol), warmed to ambient temperature, and stirred for 20 hours.
- the mixture was quenched with a 10% sodium carbonate solution, extracted with dichloromethane (3 x 100 mL), and partitioned between water and dichloromethane.
- the combined organic extracts were dried over sodium sulfate, filtered and concentrated to afford ethyl 1 -(hydroxymethyl)-4-oxo-4H-quinolizine-3-carboxylate.
- the above carboxylate was dissolved in 2.4 mL of dichloromethane and charged with triethylamine (0.074 mL, 0.53 mmol). The reaction was purged with a stream of nitrogen and cooled to 0 0 C. To this reaction was added methane sulfonyl chloride (0.042 mL, 0.53 mmol), dropwise, which was stirred for 15 minutes. The reaction was diluted with water (5 mL), extracted with dichloromethane (3 x 5 mL), and partitioned between water and dichloromethane.
- the utility of the compounds as Ml receptor positive allosteric modulators may be demonstrated by methodology known in the art, including by the assay described below,
- the 5 assay is designed to select compounds that possess modulator activity at the acetylcholine muscarinic Ml receptor or other muscarinic receptors expressed in CHOnfat cells by measuring the intracellular calcium with a FLIPR.384 Fluorometric Imaging Plate Reader System.
- the assay studies the effect of one or several concentrations of test compounds on basal or acetylcholine-stimulated Ca ⁇ + levels using FLIPR.
- Ca2+ level of each sample is measured and compared to an acetylcholine control to determine any modulatory activity.
- CHOnfat/hMl, hM2 ; hM3 or hM4 cells are plated 24 hr before the assay at a 15 density of 18,000 cells/ well ( 100 ⁇ L) in a 384 well plate.
- CHOnfat/hMl and CHOnfat/hM3 Growth Medium 90% DMEM (Hi Glucose); 10% HI FBS; 2mM L-glutamine; O.lmM NEAA; Pen-Strep; and 1 mg/ml Geneticin, are added.
- M2Gqi5CHOnfat and M4Gqi5CHOnfat cells an additional 600 ⁇ g/ml hygromycin is added.
- Assay Buffer Hanks Balanced Salt Solution, with 20 mM Hepes, 2.5 mM Probenecid (Sigma P-8761) first dissolved in IN aqueous NaOH, 1% Bovine Serum Albumin 5 (Sigma A-9647), Dye Loading Buffer: Assay Buffer plus 1% Fetal Bovine Serum and Fluo- 4AM/Pluronic Acid Mixture. 2 mM Fluo-4AM ester stock in DMSO (Molecular Probes F- 14202) Concentration of 2 ⁇ M in buffer for a final concentration of 1 ⁇ M in Assay. 20% Pluronic Acid Solution stock, with a concentration of 0.04% in Buffer, 0.02% in Assay.
- Controls 4-Br-A23187: 10 mM in DMSO; final concentration 10 ⁇ M.
- Acetylcholine 10 mM in water, working stock at both 20 ⁇ M and 30 ⁇ M in assay buffer, final concentration of 10 ⁇ M. This is used to check the maximum stimulation of the CHOKl/hMl cells. 20 ⁇ M (2x) acetylcholine is added in the preincubation part of the assay, and the 30 ⁇ M (3x) stock is added
- Screening Plate Compounds are titrated in 96-well plates (columns 2-1 1), 100% DMSO, started at a concentration of 15 mM (15Ox stock concentration), and 3-fold serial dilutions using Genesis Freedom200 System.
- Four 96-well plates are combined into a 384-well plate using Mosquito Nanolitre Pipetting System by transferring 1 ⁇ l of serial diluted compounds to each well, and 1 mM acetylcholine (10Gx stock concentration) were added as a control.
- Temo 49 ⁇ l assay buffer is added to each well of the 384-well plate right before assay.
- the cells are washed three times with 100 ⁇ L of buffer, leaving 30 ⁇ L of buffer in each well.
- the cell plate, screening plate, and agonist addition plates are placed on the platform in the FLIPR and the door is closed.
- a signal test to check background fluorescence and basal fluorescence signal is performed. Laser intensity is adjusted if necessary.
- the compounds of the following examples had activity in the aforementioned assay, generally with an IP (inflection point) of 30 ⁇ M (30,000 nM) or less.
- IP inflection point
- the inflection point is calculated from the FLIPR values, and is a measure of activity. Such a result is indicative of the intrinsic activity of the compounds in use as Ml allosteric modulators.
- IP values from the aforementioned assay for representative exemplary compounds of the invention are provided below in Table 1 below:
- IPr isopropyl t-Bu: tert-buty ⁇
- HMDS hexamethyldis ⁇ lazane
- DMEM Dulbecco's Modified Eagle Medium (High Glucose)
- FBS fetal bovine serum rt: room temperature
- aq aqueous
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009206580A AU2009206580A1 (en) | 2008-01-25 | 2009-01-15 | Quinolizidinone M1 receptor positive allosteric modulators |
CA2711487A CA2711487A1 (en) | 2008-01-25 | 2009-01-15 | Quinolizidinone m1 receptor positive allosteric modulators |
US12/812,907 US8273737B2 (en) | 2008-01-25 | 2009-01-15 | Quinolizidinone M1 receptor positive allosteric modulators |
JP2010544371A JP2011510084A (en) | 2008-01-25 | 2009-01-15 | Quinolizidinone M1 receptor positive allosteric modulator |
EP09704173A EP2244577B1 (en) | 2008-01-25 | 2009-01-15 | Quinolizidinone m1 receptor positive allosteric modulators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6242608P | 2008-01-25 | 2008-01-25 | |
US61/062,426 | 2008-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009094279A1 true WO2009094279A1 (en) | 2009-07-30 |
Family
ID=40901401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/031032 WO2009094279A1 (en) | 2008-01-25 | 2009-01-15 | Quinolizidinone m1 receptor positive allosteric modulators |
Country Status (6)
Country | Link |
---|---|
US (1) | US8273737B2 (en) |
EP (1) | EP2244577B1 (en) |
JP (1) | JP2011510084A (en) |
AU (1) | AU2009206580A1 (en) |
CA (1) | CA2711487A1 (en) |
WO (1) | WO2009094279A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013129622A1 (en) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | Heterocyclic compound and use therefor |
CN103467422A (en) * | 2013-09-13 | 2013-12-25 | 陕西步长高新制药有限公司 | Method for preparing vilazodone intermediate 5-piperazinyl-2-acyl substituted benzofuran |
CN104211668A (en) * | 2013-11-05 | 2014-12-17 | 上海馨远医药科技有限公司 | Preparation method of vilazodone intermediate and intermediate |
WO2015049574A1 (en) | 2013-10-01 | 2015-04-09 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
CN104892589A (en) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | Heterocyclic compound, preparation method therefor and use thereof |
US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011149801A1 (en) * | 2010-05-28 | 2011-12-01 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide m1 receptor positive allosteric modulators |
ES2699445T3 (en) | 2013-03-13 | 2019-02-11 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
PE20180482A1 (en) | 2015-07-06 | 2018-03-07 | Sage Therapeutics Inc | OXIESTEROLS AND METHODS OF USE OF THE SAME |
LT3436022T (en) | 2016-04-01 | 2022-06-27 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MA46351A (en) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | C7 SUBSTITUTED OXYSTEROLS AND PROCESSES AS NMDA MODULATORS |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099688A2 (en) * | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
WO2007067489A1 (en) * | 2005-12-05 | 2007-06-14 | Merck & Co., Inc. | Quinolone m1 receptor positive allosteric modulators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869500A (en) * | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
EP1596867A4 (en) | 2003-02-19 | 2006-03-22 | Merck & Co Inc | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
-
2009
- 2009-01-15 US US12/812,907 patent/US8273737B2/en active Active
- 2009-01-15 EP EP09704173A patent/EP2244577B1/en not_active Not-in-force
- 2009-01-15 JP JP2010544371A patent/JP2011510084A/en not_active Withdrawn
- 2009-01-15 AU AU2009206580A patent/AU2009206580A1/en not_active Abandoned
- 2009-01-15 WO PCT/US2009/031032 patent/WO2009094279A1/en active Application Filing
- 2009-01-15 CA CA2711487A patent/CA2711487A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099688A2 (en) * | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
WO2007067489A1 (en) * | 2005-12-05 | 2007-06-14 | Merck & Co., Inc. | Quinolone m1 receptor positive allosteric modulators |
Non-Patent Citations (2)
Title |
---|
LU ET AL.: "Transmembrane Domains 4 and 7 of the M1 Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation Switch.", J. BIOL. CHEM., vol. 276, no. 36, September 2001 (2001-09-01), pages 34098 - 34104, XP008137789 * |
See also references of EP2244577A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013129622A1 (en) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | Heterocyclic compound and use therefor |
US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
CN103467422A (en) * | 2013-09-13 | 2013-12-25 | 陕西步长高新制药有限公司 | Method for preparing vilazodone intermediate 5-piperazinyl-2-acyl substituted benzofuran |
AU2014330880B2 (en) * | 2013-10-01 | 2019-01-31 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
WO2015049574A1 (en) | 2013-10-01 | 2015-04-09 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
CN105873927A (en) * | 2013-10-01 | 2016-08-17 | 卫材R&D管理有限公司 | 4-azaindole derivatives |
EP3489237A1 (en) | 2013-10-01 | 2019-05-29 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
US9926312B2 (en) | 2013-10-01 | 2018-03-27 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
US10072005B2 (en) | 2013-10-01 | 2018-09-11 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
CN105873927B (en) * | 2013-10-01 | 2017-11-28 | 卫材R&D管理有限公司 | 4 7-azaindole derivatives |
CN104211668B (en) * | 2013-11-05 | 2016-08-17 | 上海馨远医药科技有限公司 | The preparation method of a kind of vilazodone intermediate and intermediate |
CN104211668A (en) * | 2013-11-05 | 2014-12-17 | 上海馨远医药科技有限公司 | Preparation method of vilazodone intermediate and intermediate |
CN104892589A (en) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | Heterocyclic compound, preparation method therefor and use thereof |
AU2015226578B2 (en) * | 2014-03-07 | 2017-11-23 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic compounds, process for preparation of the same and use thereof |
US10174011B2 (en) | 2014-03-07 | 2019-01-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic compounds, process for preparation of the same and use thereof |
EP3115361A4 (en) * | 2014-03-07 | 2017-04-26 | Shanghai Institute Of Materia Medica Chinese Academy of Sciences | Heterocyclic compounds, and preparation method and use thereof |
CN106132956A (en) * | 2014-03-07 | 2016-11-16 | 中国科学院上海药物研究所 | Heterocycle compound, Preparation Method And The Use |
Also Published As
Publication number | Publication date |
---|---|
EP2244577A1 (en) | 2010-11-03 |
CA2711487A1 (en) | 2009-07-30 |
US8273737B2 (en) | 2012-09-25 |
US20110112077A1 (en) | 2011-05-12 |
EP2244577A4 (en) | 2011-07-27 |
EP2244577B1 (en) | 2012-10-31 |
JP2011510084A (en) | 2011-03-31 |
AU2009206580A1 (en) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2483275B1 (en) | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | |
EP2244577B1 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
EP2515656B1 (en) | Aminobenzoquinazolinone m1 receptor positive allosteric modulators | |
EP2252151B1 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
EP2312949A1 (en) | N-heterocyclic m1 receptor positive allosteric modulators | |
WO2010047990A1 (en) | Fused heterocyclic m1 receptor positive allosteric modulators | |
EP2340247B1 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
EP2252299A1 (en) | Fused pyridone m1 receptor positive allosteric modulators | |
EP2212322A1 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
EP2283015A2 (en) | 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators | |
EP2268280B1 (en) | Quinolizidinone M1 receptor positive allosteric modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09704173 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009206580 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2711487 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009206580 Country of ref document: AU Date of ref document: 20090115 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12812907 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009704173 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010544371 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |